用重组人血管内皮抑制素联合放化疗治疗局部晚期头颈部鳞癌的疗效分析
|
摘要
目的 :探讨使用重组人血管内皮抑制素联合放化疗治疗局部晚期头颈部鳞癌的疗效。方法 :将2015年2月至2017年11月期间阆中市人民医院收治的72例局部晚期头颈部鳞癌患者根据入院顺序的单双号分为对照组和研究组。对两组患者均进行放疗和化疗。在此基础上,为研究组患者使用重组人血管内皮抑制素进行治疗。然后观察两组患者病情控制的情况、生活质量评分及发生不良反应的情况。结果 :治疗后,两组患者病情的控制率相比,P>0.05。治疗后,研究组患者SF-36中的躯体功能评分、社会功能评分、活力评分及精神健康状况评分均高于对照组患者,P<0.05。治疗期间,两组患者恶心呕吐、贫血、放射性皮炎及血小板降低的发生率相比,P>0.05。结论 :使用重组人血管内皮抑制素联合放化疗治疗局部晚期头颈部鳞癌可获得良好的疗效,提高患者的生活质量,且不会增加其不良反应的发生率。
objective: to investigate the efficacy of recombinant human vascular endostatin combined with chemoradiotherapy in the treatment of locally advanced head and neck squamous cell carcinoma. Methods: 72 patients with locally advanced head and neck squamous cell carcinoma admitted to langzhong people's hospital from February 2015 to November 2017 were divided into control group and research group according to the even-odd number sequence. Both groups were treated with radiotherapy and chemotherapy. On this basis, recombinant human vascular endostatin was used in the study group. Then the condition control, quality of life score and adverse reactions were observed. Results: after treatment, the control rate of patients' condition in the two groups was compared, P > 0.05. After treatment, the scores of physical function, social function, vitality and mental health status of the patients in the study group were all higher than those in the control group(P < 0.05). During the treatment period, the incidence of nausea, vomiting, anemia, radioactive dermatitis and thrombocytopenia in the two groups was compared, P > 0.05. Conclusion:recombinant human vascular endostatin combined with chemoradiotherapy in the treatment of locally advanced head and neck squamous cell carcinoma can achieve good efficacy, improve the quality of life of patients, and do not increase the incidence of adverse reactions.
objective: to investigate the efficacy of recombinant human vascular endostatin combined with chemoradiotherapy in the treatment of locally advanced head and neck squamous cell carcinoma. Methods: 72 patients with locally advanced head and neck squamous cell carcinoma admitted to langzhong people's hospital from February 2015 to November 2017 were divided into control group and research group according to the even-odd number sequence. Both groups were treated with radiotherapy and chemotherapy. On this basis, recombinant human vascular endostatin was used in the study group. Then the condition control, quality of life score and adverse reactions were observed. Results: after treatment, the control rate of patients' condition in the two groups was compared, P > 0.05. After treatment, the scores of physical function, social function, vitality and mental health status of the patients in the study group were all higher than those in the control group(P < 0.05). During the treatment period, the incidence of nausea, vomiting, anemia, radioactive dermatitis and thrombocytopenia in the two groups was compared, P > 0.05. Conclusion:recombinant human vascular endostatin combined with chemoradiotherapy in the treatment of locally advanced head and neck squamous cell carcinoma can achieve good efficacy, improve the quality of life of patients, and do not increase the incidence of adverse reactions.
引文
[1]邢镨元,郝学志,胡兴胜,等.重组人血管内皮抑制素在晚期肺鳞癌治疗中的临床应用[J].中国肺癌杂志,2016,19(10):670-674.
[2]郑瑄,蒋华,俞翔.重组人血管内皮抑制素联合化疗治疗晚期肺鳞癌的疗效及对相关指标的影响[J].医学临床研究,2018,35(4):776-778.
[3]陈宇,吴伟莉,金风,等.时间调节诱导化疗序贯洛铂同期放化疗治疗局部晚期头颈部鳞癌临床分析[J].肿瘤防治研究,2017,44(10):689-693.
[2]郑瑄,蒋华,俞翔.重组人血管内皮抑制素联合化疗治疗晚期肺鳞癌的疗效及对相关指标的影响[J].医学临床研究,2018,35(4):776-778.
[3]陈宇,吴伟莉,金风,等.时间调节诱导化疗序贯洛铂同期放化疗治疗局部晚期头颈部鳞癌临床分析[J].肿瘤防治研究,2017,44(10):689-693.